Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalon Globocare Corp ALBT

Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering... see more

Recent & Breaking News (NDAQ:ALBT)

Avalon GloboCare to Participate in the 35th Annual Roth Conference

GlobeNewswire March 3, 2023

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

GlobeNewswire February 13, 2023

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

GlobeNewswire January 17, 2023

Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors

GlobeNewswire January 11, 2023

Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology

GlobeNewswire January 3, 2023

Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company's Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services

GlobeNewswire December 14, 2022

Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC

GlobeNewswire December 12, 2022

Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"

GlobeNewswire November 9, 2022

Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

GlobeNewswire November 8, 2022

Avalon Globocare to Present at the LD Micro Main Event XV on October 26th

Newsfile October 19, 2022

Avalon GloboCare Receives Allowance for Joint U.S. Patent

GlobeNewswire September 29, 2022

Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society

GlobeNewswire August 8, 2022

Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

GlobeNewswire June 30, 2022

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

GlobeNewswire May 25, 2022

Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

GlobeNewswire May 18, 2022

Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications

GlobeNewswire April 27, 2022

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

GlobeNewswire February 14, 2022

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

GlobeNewswire January 4, 2022

Avalon GloboCare's Chairman Converts Debt into Common Stock at 45% Premium to Market

GlobeNewswire December 22, 2021

Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development

GlobeNewswire December 9, 2021